Learn the role that genes play in the risk of developing the early- and late-onset forms of Alzheimer’s disease.
Genes: A Blueprint for Health and Disease
The genes encoded in our DNA are profoundly involved in many aspects of our health. They act as a sort of blueprint for the construction, operation, and repair of our bodies throughout life. Genes provide instructions for the creation and regulation of our body’s building blocks. We inherit one copy of each gene from each of our parents, which is one reason why every person (excluding identical siblings) has a unique appearance and metabolism.
The effects of a gene can be dramatically changed by mutation of even one pair of its molecules. Specific versions of genes, called alleles, are passed down through a family’s lineage, potentially creating an entire population of people who share a healthy characteristic such as resistance to cancer; a more neutral characteristic such as eye color; or a heightened risk for a specific disease such as Alzheimer’s disease (AD).
Many of us have learned about Mendel, who was an Austrian monk, and the pea plants he bred as he discovered basic principles of genetic inheritance. Just as with Mendel’s plants, some physical characteristics can be transmitted to our offspring through inheritance of even one version of a gene. Many diseases are inherited this way, too.
Autosomal dominant is a term for a gene version that is so influential just one copy will dominate other factors. The gene is located on one of the 22 paired chromosomes, (not the X or Y sex chromosomes), hence the term autosomal. It also overwhelms the effect of any other version of the gene that is present, which is why it is called dominant. To answer Bill’s question about whether Alzheimer’s is a genetic disease: AD can be transmitted this way, but such direct transmission from parent to child is actually rare.
Research advances in genetics and proteomics (the large-scale study of proteins) have allowed for the screening of astoundingly large numbers of genes and proteins. This approach identifies a more complex relationship between genes and diseases. Gene or protein variations, linked statistically with the presence of specific diseases, sometimes point the way to a deeper understanding of disease process or potential treatments. Instead of expecting one gene to bear responsibility for the transmission of a disease, we have now learned that susceptibility to a disease may be influenced by the presence of one or more genes related less directly to the disease itself.
Early-Onset Alzheimer’s Disease
An estimated one in twenty people with AD have the early-onset form (EOAD), clinically apparent by age 60. Only a small percentage of these have developed the disease because of an autosomal dominant inherited version.
Three separate gene versions account for the large majority of inherited early-onset AD. These genes, APP (amyloid precursor protein), presenilin 1 (PSEN1) and presenilin 2 (PSEN2), all affect the development of toxic beta amyloid, a protein infamous for its participation in AD’s amyloid plaques. PSEN1 is the most common, followed by APP. PSEN2 mutations have been found in only a small number of families.
Much more commonly, the clinical symptoms and signs of AD become apparent after age 60, and the condition is called late-onset Alzheimer’s disease (LOAD or “sporadic AD”). In the case of LOAD, a number of genes have been identified by these statistical approaches.
The most important of these is the E4 version of the apolipoprotein gene, referred to as ApoE4. The E4 version is known to increase the risk of LOAD by a factor of 2 or 3. People who have two copies of E4 have a 12-fold risk. Apolipoprotein E is thought to interact with the accumulation and removal of the amyloid protein, but its exact role in AD is still being determined. Interestingly, the E2 version may increase resistance to the development of AD.
- Alzheimer’s Disease Toolkit (Helpful Information to Understand and Manage Alzheimer's Disease)
- Expert Information on Alzheimer's Disease (Articles)
- What Is Your Risk?—Heredity and Late-Onset Alzheimer’s Disease (Article)
- Early-Onset Alzheimer’s Disease (Article)
- Decreasing Your Risk of Alzheimer's Disease (Article)
- Understanding Alzheimer's Disease: It's Not Just Forgetfulness (Publication)
- Mayeux R, Stern Y. Epidemiology of Alzheimer Disease. Cold Spring Harb Perspect Med. 2012 Aug; 2(8): a006239. doi: 10.1101/cshperspect.a006239
- Verheijen J, Sleegers K. Understanding Alzheimer Disease at the interface between genetics and transcriptomics. Trends in Genetics 2018, https://doi.org/10.1016/j.tig.2018.02.007
- Pihlstrom L, Wiethoff S, Houlden H. Chapter 22. Genetics of neurodegenerative diseases: an overview. Handbook of Clinical Neurology. Vol 145. 2018. http://dx.doi.org/10.1016/B978-0-12-802395-2.00022-5
This content was last updated on: October 2, 2018
The information provided here is a public service of the BrightFocus Foundation and should not in any way substitute for personalized advice of a qualified healthcare professional; it is not intended to constitute medical advice. Please consult your physician for personalized medical advice. BrightFocus Foundation does not endorse any medical product, therapy, or resources mentioned or listed in this article. All medications and supplements should only be taken under medical supervision. Also, although we make every effort to keep the medical information on our website updated, we cannot guarantee that the posted information reflects the most up-to-date research.
These articles do not imply an endorsement of BrightFocus by the author or their institution, nor do they imply an endorsement of the institution or author by BrightFocus.
Some of the content may be adapted from other sources, which will be clearly identified within the article.